Posted on: November 23, 2022
This BCCDC guidance document is updated as follows: REVISED guidance regarding the use of tixagevimab/cilgavimab for pre-exposure prophylaxis against COVID-19 considering currently circulating Variants of Concern in BC.
Information is considered to be true and correct at the date of publication, changes in circumstances after the time of publication may impact on the accuracy of the information.